Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Orlando Immunology Center
mi
from
Orlando, FL
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Apex Clinical Research
mi
from
Tampa, FL
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Apex Clinical Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
The Ruth M. Rothstein CORE Center
mi
from
Chicago, IL
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
The Ruth M. Rothstein CORE Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
The Research Institute
mi
from
Springfield, MA
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
The Research Institute
mi
from
Springfield, MA
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Harper University Hospital
mi
from
Detroit, MI
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Harper University Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Southwest CARE Center
mi
from
Santa Fe, NM
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Southwest CARE Center
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
SSM Health Dean Medical Group
mi
from
Madison, WI
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
SSM Health Dean Medical Group
mi
from
Madison, WI
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Altanta
mi
from
Atlanta, GA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Altanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research (ACR)
mi
from
Boise, ID
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research (ACR)
mi
from
Boise, ID
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research (ACR)
mi
from
Salt Lake City, UT
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research (ACR)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Consortium Arizona
mi
from
Tempe, AZ
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Consortium Arizona
mi
from
Tempe, AZ
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Ruane Clinical Research Group
mi
from
Los Angeles, CA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Ruane Clinical Research Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
CareOne Research
mi
from
North Hollywood, CA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
CareOne Research
mi
from
North Hollywood, CA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Montana Medical Research
mi
from
Missoula, MT
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Montana Medical Research
mi
from
Missoula, MT
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Aventiv Research
mi
from
Columbus, OH
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Aventiv Research
mi
from
Columbus, OH
Click here to add this to my saved trials
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Anticipated and Perceived Benefits Following Hepatitis C Treatment
A Qualitative and Quantitative Evaluation of Patients' Anticipated and Perceived Treatment Benefits Following HCV Viral Eradication
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Anticipated and Perceived Benefits Following Hepatitis C Treatment
A Qualitative and Quantitative Evaluation of Patients' Anticipated and Perceived Treatment Benefits Following HCV Viral Eradication
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants
Status: Enrolling
Updated:  12/31/1969
PRA Health Sciences
mi
from
Salt Lake City, UT
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants
Status: Enrolling
Updated: 12/31/1969
PRA Health Sciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
The Institute for Liver Health
mi
from
Chandler, AZ
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
The Institute for Liver Health
mi
from
Chandler, AZ
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Arkansas Gastroenterology
mi
from
North Little Rock, AR
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Arkansas Gastroenterology
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Southern California Liver Center
mi
from
Coronado, CA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Southern California Liver Center
mi
from
Coronado, CA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Ruane Clinical Research Group
mi
from
Los Angeles, CA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Ruane Clinical Research Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
California Liver Research Institute
mi
from
Pasadena, CA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
California Liver Research Institute
mi
from
Pasadena, CA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Huntington Medical Research Institutes Liver Center
mi
from
Pasadena, CA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Huntington Medical Research Institutes Liver Center
mi
from
Pasadena, CA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Inland Empire Liver Foundation
mi
from
Rialto, CA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Inland Empire Liver Foundation
mi
from
Rialto, CA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Medical Associates Research Group
mi
from
San Diego, CA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Medical Associates Research Group
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Integrity Clinical Research, LLC
mi
from
Doral, FL
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Integrity Clinical Research, LLC
mi
from
Doral, FL
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
IMIC, Inc.
mi
from
Miami, FL
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
IMIC, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Gastrointestinal Diseases Research
mi
from
Columbus, GA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Gastrointestinal Diseases Research
mi
from
Columbus, GA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Gastrointestinal Specialists of Georgia
mi
from
Marietta, GA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Gastrointestinal Specialists of Georgia
mi
from
Marietta, GA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Delta Research Partners, LLC
mi
from
Bastrop, LA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Delta Research Partners, LLC
mi
from
Bastrop, LA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Sandra Atlas Bass Center for Liver Diseases and Transplantation
mi
from
Manhasset, NY
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Sandra Atlas Bass Center for Liver Diseases and Transplantation
mi
from
Manhasset, NY
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Cumberland Research Associates
mi
from
Fayetteville, NC
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Cumberland Research Associates
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
University Gastroenterology
mi
from
Providence, RI
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
University Gastroenterology
mi
from
Providence, RI
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Gastro One
mi
from
Germantown, TN
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Gastro One
mi
from
Germantown, TN
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Quality Medical Research Pllc
mi
from
Nashville, TN
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Quality Medical Research Pllc
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Texas Clinical Research Institute
mi
from
Arlington, TX
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Texas Clinical Research Institute
mi
from
Arlington, TX
Click here to add this to my saved trials